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Over the past 30 years a huge amount of information has
been gathered about tumour biology and the carcinogenic
process. It is known that cancer develops as a result of a
disturbance in the critical balance between the rate of
cell-cycle progression and cell growth on one hand, and
apoptosis on the other. Research has increased understand-
ing of the unique features that enable tumour cells to grow
and spread. Of particular interest are the tyrosine kinases –
signalling molecules involved in cell survival, motility,
differentiation and mitogenesis. Genetic and structural
alterations in tyrosine kinases are associated with a large
number of cancers.1 Targeted inhibition of tyrosine kinases
and their signalling cascades has been shown to be a suc-
cessful anticancer strategy, the most successful to date
being imatinib in chronic myeloid leukaemia (CML) and gas-
trointestinal stromal tumours.2 As understanding of critical
downstream signalling pathways involved in tumourigenesis
becomes more sophisticated, so will the ability to selectively
inhibit these pathways, and ultimately, to treat all types of
cancer.er Ltd. All rights reserved2. Oncogenic cellular transformation
Tumour cells are cells that have lost the ability to undergo dif-
ferentiation, senescence and apoptosis. Furthermore, they
have lost the normal mechanistic checks that would curb
over-proliferation. Therefore, tumour cells can be seen as
highly specialised cells that can proliferate independently of
extracellular mitotic signals. Other hallmarks of tumour
development include the ability to metastasise to distant sites
by migration through the extracellular matrix, induction of
angiogenesis and invasion of tissue. These unique features
of tumour cells are often mediated by signalling pathways
that have become deregulated. Therefore, these pathways
represent promising targets for anticancer therapies. How-
ever, one of the difficulties in developing successful com-
pounds to target these signalling pathways is that they are
highly complex. Both positive and negative regulatory ele-
ments are present, and there is often cross-talk with other
pathways, such that selectively inhibiting oncogenic path-
ways while leaving normal physiological pathways intact be-
comes incredibly difficult. Understanding of the mutations
and genetic rearrangements involved in tumourigenesis has
been greatly helped by the publication of the human genome..
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now be pinpointed. For example, it is now known that tu-
mours often overexpress certain kinases that have effects
on signalling pathways, leading to abnormal proliferation
and metastasis. These kinases and their signalling cascades
are therefore excellent targets for anticancer therapeutics,
which can be designed to specifically inhibit, moderate or
interfere with their function.
3. Tyrosine kinase inhibitors as cancer
treatments
The human genome includes more than 20,000 genes, of
which at least 500 encode protein kinases – the ‘human ki-
nome’ (Fig. 1).3 Protein kinases are involved in the regulation
of a wide range of biological processes. Because of their regu-
latory function, protein kinases play a major role in human
disease, particularly cancer and inflammation.4 Certain ki-
nase signalling pathways are targeted much more frequently
by oncogenic mutations than others. One of the most fre-
quently implicated classes of kinases in cancer is the tyrosine
kinases. Within the human kinome there are more than 90
tyrosine kinases, of which 38 are cytoplasmic (divided into
10 subfamilies) and 58 are receptor tyrosine kinases (RTKs; di-
vided into 20 subfamilies).3
3.1. RTKs
RTKs are characterised by a catalytic cytoplasmic domain.
Upon ligand-induced dimerisation, the cytoplasmic domains
transphosphorylate each other. The phosphorylated tyrosines
then initiate a signal cascade via recruitment of proteins with
phosphotyrosine binding or protein tyrosine-binding do-
mains (Fig. 2). These signalling cascades ultimately lead to
changes in gene expression affecting mitogenesis, survival,
differentiation and motility.5 Perturbation of RTK signalling
by point mutations, genomic rearrangements or other genetic
alterations can result in deregulation of activity, such that the
kinase becomes a potent oncoprotein capable of causing
malignant transformation. Such aberrant signalling through
RTKs is implicated in a number of different cancers.1 RTKs
are therefore excellent targets for the development of anti-
cancer therapies.
3.1.1. The EGFR receptor (ErbB) family
One the most important RTK subfamilies in cancer is the epi-
dermal growth factor receptor (EGFR) family, also known as
the ErbB family. Studies in the late 1980s using murine NIH
3T3 fibroblasts demonstrated that hyperstimulation of the
EGFR signalling pathway by overexpression of human EGFR
was sufficient for oncogenic transformation.6
The EGFR family comprises four membrane-bound tyro-
sine kinases (Fig. 3): EGFR (Her1/ErbB1), Her2/neu (ErbB2),
Her3 (ErbB3) and Her4 (ErbB4). Each receptor has typical RTK
topology – an extracellular ligand-binding domain, a trans-
membrane domain, and a cytoplasmic domain with intrinsic
kinase activity (except Her3, which requires dimerisation
with other members for kinase activity).7 Within the family
there is some sequence homology, but members differ in
terms of their binding affinity for different EGF-like growthfactors and degree of kinase activity.8 A large number of mol-
ecules – known as EGF-like growth factors – are able to acti-
vate the EGFR family members, including transforming
growth factor (TGF)-a, neuregulins, amphiregulin, epiregulin,
heparin-binding EGF and EGF itself.9 Following binding, both
homo- and heterodimers can form, with each dimer combi-
nation activating a different signalling pathway. For example,
EGFR–Her2 heterodimers are associated with a more intense
and sustained proliferative signal than EGFR–EGFR homodi-
mers.10,11 Factors that influence the formation of the different
dimer combinations include the ligands bound to the recep-
tors, as well as the relative abundance of each receptor. The
number of possible ligands and dimer combinations results
in a high level of complexity and diversity to the downstream
signalling cascades induced. Depending on the particular li-
gands and receptors involved, outputs of EGFR signalling
can affect apoptosis; angiogenesis; cellular migration, inva-
sion and metastasis; differentiation; adhesion; or prolifera-
tion (Fig. 4). Important signalling pathways induced by EGFR
activation include the mitogen-activated protein kinase
(MAPK) pathway, which mediates cellular proliferation, phos-
phoinositide 3-kinase and the anti-apoptotic Akt/protein
kinase B (PKB) pathway.2 Overstimulation of EGFR signalling
pathways in cancer may be due to increased production of
ligands, receptor gene amplification occurring as a result
of mutations or genetic rearrangements, or overexpression
of the receptors. Furthermore, overexpression of EGFR is asso-
ciated with a poor prognosis and the development of resis-
tance to chemotherapy, radiotherapy and hormone therapy
in breast, ovarian, colorectal, head and neck, and non-
small-cell lung cancer (NSCLC).13–23
Several EGFR inhibitors have been developed as antican-
cer therapies: gefitinib, erlotinib and cetuximab against
EGFR, and trastuzumab against Her2. Both gefitinib and erl-
otinib are small molecule inhibitors that compete for the
adenosine triphosphate (ATP)-binding site in the cytoplas-
mic tail of the EGFR tyrosine kinase. Gefitinib initially re-
ceived conditional approval for NSCLC from the Food and
Drug Administration (FDA) in May 2003, based on response
rates in uncontrolled phase II studies. However, in phase III
trials, although gefitinib showed a statistically significant
tumour shrinkage, it failed to show a survival advantage
over placebo.24 Better results have been achieved with
erlotinib. In a phase III clinical trial of patients with
advanced-stage (Stage IIIB or IV) NSCLC and 1 or 2 prior
chemotherapy regimens, erlotinib was associated with a 2-
month benefit in terms of overall survival compared with
placebo (6.7 versus 4.7 months; 95% CI [0.58–0.85]; P <
0.001).25
Cetuximab is a monoclonal human–murine chimeric
antibody that competes with the ligand-binding site of
EGFR. Cetuximab has shown significant anti-tumour activity
in phase III studies on head and neck cancer and colorectal
cancer when added to traditional radiation or chemother-
apy. In a study of irinotecan-refractory metastatic colorectal
cancer, patients receiving cetuximab in combination with
irinotecan chemotherapy showed a median time to progres-
sion of 4.1 months compared with just 1.5 months in pa-
tients receiving cetuximab alone (P < 0.001).26 Combination
therapy was also associated with a greater median survival
Fig. 1 – The human kinome. Kinome dendrogram figure courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com)
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trial in head and neck squamous cell carcinoma demon-
strated that cetuximab plus radiation therapy was associ-
ated with a significantly greater median survival at 2 years
compared with radiation alone (54 months versus 28
months; P = 0.02).27Excellent results have been obtained using trastuzumab in
the adjuvant treatment of Her2-positive breast cancer. Trast-
uzumab is a humanised monoclonal antibody that binds to
the extracellular domain of Her2. Results from the combined
studies by the National Surgical Adjuvant Breast and Bowel
Project trial (B-31), the North Central Cancer Treatment Group
Fig. 2 – Tyrosine kinase receptors. A tyrosine kinase receptor complex is activated by ligand binding (in this case,
platelet-derived growth factor [PDGF]), triggering multiple signal transduction pathways within the cell.
Fig. 3 – The EGFR (ErbB) family and their ligands.
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national Group [BIG] 01-01) trial all showed highly significant
reductions in the risk of recurrence.28,29 The absolute benefit
in terms of disease-free survival in the HERA trial was 8.4%
(95% CI [2.1–14.8]) at a 2-year follow-up.30 The joint analysis
of B-31 and N9831 trials showed an absolute benefit at four
years post-follow-up of 18.2% (95% CI [8.1–15.4]), exceeding
all previously reported benefits in breast cancer.28,29 Further-
more, there is growing evidence that trastuzumab-combined
chemotherapy elicits high levels of pathological complete
response in the neoadjuvant setting.313.2. Cytoplasmic tyrosine kinases
Although there are many more RTK inhibitors in develop-
ment compared with cytoplasmic tyrosine kinase inhibitors,
the first clinically successful tyrosine kinase inhibitor was
against a cytoplasmic kinase; the Bcr-Abl tyrosine kinase is
expressed in more than 95% of patients with CML and
around 25–30% of adults with acute lymphoblastic leukaemia
(ALL).2,32 The Bcr-Abl gene is a hybrid resulting from a trans-
location between chromosomes 9 and 22.33 Whereas the activ-
ity of the normal Abl tyrosine kinase is tightly regulated, the
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activates oncogenic signalling pathways, and has been
shown to induce leukaemia in both experimental animals
and humans.33–35 Bcr-Abl induces phosphorylation in a num-
ber of target proteins, including Crkl, Shc, Syp, Fes, Vav and
paxillin.36–40 Bcr-Abl is also thought to interact with the Ras
signalling pathway via binding to GRB2 (growth factor recep-
tor bound protein 2) and SOS (son of sevenless),41 and the
JAK/STAT (Janus kinase/signal transducers and activators of
transcription) signalling pathway.42 The activation of these
signalling pathways by Bcr-Abl results in increased cell adhe-
sion, inhibition of apoptosis, and promotion of anti-apopto-
tic proteins, upregulation of cell survival genes and
growth-factor independent growth – all the hallmarks of
tumourigenesis. The degree of transforming activity of Bcr-
Abl appears to correlate with the degree of tyrosine kinase
activity.35
The small molecule, imatinib, was designed to block the
ATP-binding site of Bcr-Abl, preventing phosphorylation and
thus inhibiting kinase activity. Imatinib blocks proliferation
and induces apoptosis of Bcr-Abl-expressing cells. Following
treatment, response to imatinib is rapid, with most patients
achieving a complete haematological response within the
first 4–6 weeks of therapy. Furthermore, more than 50% of pa-
tients achieved a complete cytogenetic response within 3
months of initiating treatment.2 Indeed, patients treated with
imatinib showed significantly better results than patients
treated with conventional interferon (IFN)-a therapy with re-
gard to haematological and cytogenetic response, progression
to accelerated phase or blast crisis and discontinuation of
treatment due to intolerance.43Other cytoplasmic tyrosine kinases implicated in cancer in-
clude the Src family of kinases. Src kinases are overexpressed
in a range of human cancers including colon, breast, pancreas,
ovarian, prostate and lung cancer.44–49 Src (encoded by the c-src
gene) is normally maintained in an inactive state within the
cell via phosphorylation of a C-terminal tyrosine residue
(Tyr527 in humans). During normal cell growth, Src can be
transiently activated during mitosis. However, in tumour cells,
Src is de-repressed as a result of disruption to the regulatory
progresses that would normally suppress Src activity.44 This
is thought to be mediated via enhanced levels of protein-
tyrosine phosphatase, which de-phosphorylate the C-terminal
Tyr527, or mutations that prevent establishment of the inactive
phosphorylated Tyr527 conformation.44,50
4. Resistance to targeted therapy
A key hurdle to overcome in order to realise the full potential of
targeted kinase inhibitors for the treatment of cancer will be
the emergence of drug resistance in treated patients. Already,
mutant forms of Bcr-Abl, Kit and EGFR have been found that
confer resistance to imatinib, gefitinib and erlotinib. Resistance
to imatinib is an increasing problem, with as many as 80–90% of
patients with late-phase CML (blast crisis) developing imatinib
resistance. Several mechanisms of resistance have been iden-
tified, including gene amplification and mutations that inter-
fere with imatinib binding to Bcr-Abl.51–53 To overcome
imatinib resistance, molecules have been developed that have
increased binding affinity for Bcr-Abl. One of these molecules is
dasatinib (BMS-354825), a novel, orally available, dual Src/Abl
kinase inhibitor that has demonstrated significant potential
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greater potency than imatinib and has preclinical activity
against 14 out of 15 imatinib-resistant Bcr-Abl mutants.54
Currently undergoing Phase II/III trials, dasatinib has been
shown to be effective in patients with CML who have pro-
gressed on imatinib. Data presented at the annual meeting
of the American Society of Hematologists (ASH) in 2004 found
that 86% of patients who received dasatinib achieved
complete haematological response within 9 months. These
results were further supported by data presented at the
annual meeting of the American Society of Clinical Oncology
(ASCO) 2004, with dasatinib producing a complete haemato-
logical response in 50% of patients who had accelerated dis-
ease and 28% of those who were in blast crisis.
5. The future of targeted therapy
One of the great advantages of targeted anticancer therapies
is that they generally have very acceptable toxicity profiles
compared with some of the older cytotoxic agents. This fea-
ture, combined with an excellent clinical efficacy, will make
them attractive agents to use as first-line treatments. How-
ever, given the nature of their mode of action, targeted thera-
pies will be of greatest benefit to those patients whose
tumours are expressing the particular molecule being tar-
geted. Therefore, it will become necessary to perform diag-
nostics to ensure patients receive the appropriate targeted
therapy for the molecular profile of their tumour.
6. ConclusionsAberrant, particularly constitutively active, signalling through
cytoplasmic and receptor tyrosine kinases has been impli-
cated in a number of cancers, providing a clear rationale for
targeting these molecules in anticancer therapy. Following
the great success of imatinib, several tyrosine kinase inhibi-
tors have been developed as anticancer therapies, including
gefitinib, erlotinib, trastuzumab and cetuximab. Despite ad-
vances in the understanding of oncogenic signalling path-
ways, results from clinical trials have been mixed. This may
be in part due to the complexity and indeed redundancy in
such pathways, but also due to problems in progressing from
animal models to humans. Animal models are limited in their
ability to simulate human cancer and better preclinical mod-
els are required. Furthermore, better surrogate markers that
predict anti-tumour effects, as well as recognition of appro-
priate clinical endpoints, will enable targeted therapies that
are most likely to be successful in specific patients to be
quickly and easily identified.
Emerging resistance to targeted therapies will need to be
addressed as the fight against cancer moves forward. A better
understanding of the molecular basis behind the development
of resistance will enable new compounds to be developed and
existing agents intelligently selected against drug-resistant
mutants. In summary, as understanding of the pathways in-
volved in tumour proliferation and growth becomes clearer,
and methods of screening compounds for clinical activity be-
come more sophisticated, it will only be a question of time be-
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